Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALDX logo ALDX
Upturn stock ratingUpturn stock rating
ALDX logo

Aldeyra The (ALDX)

Upturn stock ratingUpturn stock rating
$4.52
Last Close (24-hour delay)
Profit since last BUY42.59%
upturn advisory
Consider higher Upturn Star rating
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/09/2025: ALDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $8.67

1 Year Target Price $8.67

Analysts Price Target For last 52 week
$8.67 Target price
52w Low $1.14
Current$4.52
52w High $7.2

Analysis of Past Performance

Type Stock
Historic Profit -33.78%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/09/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 259.35M USD
Price to earnings Ratio -
1Y Target Price 8.67
Price to earnings Ratio -
1Y Target Price 8.67
Volume (30-day avg) 7
Beta 0.68
52 Weeks Range 1.14 - 7.20
Updated Date 07/9/2025
52 Weeks Range 1.14 - 7.20
Updated Date 07/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.97

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -32.6%
Return on Equity (TTM) -65.19%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 184856459
Price to Sales(TTM) -
Enterprise Value 184856459
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.5
Shares Outstanding 59895600
Shares Floating 47667904
Shares Outstanding 59895600
Shares Floating 47667904
Percent Insiders 3.13
Percent Institutions 56.16

ai summary icon Upturn AI SWOT

Aldeyra The

stock logo

Company Overview

overview logo History and Background

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for immune-mediated diseases. Founded in 2004, they initially focused on aldehyde dehydrogenase (ALDH) inhibition, leading to their pipeline of product candidates.

business area logo Core Business Areas

  • Ophthalmology: Focuses on developing therapies for ocular diseases, including allergic conjunctivitis and dry eye disease.
  • Systemic Immunometabolic Diseases: Explores treatments for systemic diseases linked to immune system dysfunction and metabolic processes.

leadership logo Leadership and Structure

Dr. Todd C. Brady is the President and Chief Executive Officer. The company has a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Reproxalap: Reproxalap is Aldeyra's lead product candidate, indicated for the treatment of allergic conjunctivitis and dry eye disease. It competes with established treatments like cyclosporine (Restasis) from AbbVie and lifitegrast (Xiidra) from Novartis. Market share data is evolving pending FDA approval and commercial launch. Revenue data is projected. Competitors include AbbVie (Restasis), Novartis (Xiidra) and Sun Pharma (Cequa).
  • ADX-2191: ADX-2191 is a intravitreal formulation of methotrexate in development for the treatment of proliferative vitreoretinopathy (PVR). Competitors are off-label methotrexate. The company is also evaluating the unmet needs that ADX-2191 is going to solve.

Market Dynamics

industry overview logo Industry Overview

The ophthalmology market is growing due to aging populations and increased screen time, leading to higher rates of eye diseases. The immunometabolic disease market is also expanding due to increased understanding of these complex conditions.

Positioning

Aldeyra Therapeutics is positioned as an innovator with a novel ALDH inhibitor platform, targeting unmet needs in specific ocular and systemic disease segments.

Total Addressable Market (TAM)

The global dry eye disease market is projected to reach billions of dollars. Aldeyra is positioned to capture a portion of this TAM with Reproxalap, pending FDA approval and commercial success.

Upturn SWOT Analysis

Strengths

  • Novel ALDH inhibitor platform
  • Lead product candidate (Reproxalap) with promising clinical data
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Limited commercialization experience
  • Dependence on successful clinical trials and FDA approval
  • High cash burn rate
  • Reliance on a few key product candidates

Opportunities

  • FDA approval and commercial launch of Reproxalap
  • Expansion of ALDH inhibitor platform to new indications
  • Strategic partnerships and collaborations
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from established pharmaceutical companies
  • Patent challenges
  • Generic entry.

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • NVS
  • SNY

Competitive Landscape

Aldeyra's key advantage lies in its novel ALDH inhibitor mechanism, but it faces strong competition from established players with marketed products and larger commercial infrastructure.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is largely tied to the progression of clinical trials for Reproxalap and other product candidates.

Future Projections: Future projections depend heavily on FDA approval and successful commercialization of Reproxalap.

Recent Initiatives: Recent initiatives include completing clinical trials for Reproxalap, submitting regulatory filings to the FDA, and expanding the pipeline through preclinical research.

Summary

Aldeyra Therapeutics is a clinical-stage biotechnology company with a focus on immune-mediated diseases, particularly in ophthalmology. The company's success hinges on the approval and commercialization of Reproxalap, its lead product candidate. Despite the promise of its novel ALDH inhibitor platform, Aldeyra faces challenges including regulatory hurdles, competition from established pharmaceutical giants, and a high cash burn rate. Potential investors should carefully monitor clinical trial outcomes and regulatory decisions.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Aldeyra Therapeutics Investor Relations
  • SEC Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aldeyra The

Exchange NASDAQ
Headquaters Lexington, MA, United States
IPO Launch date 2014-05-02
CEO, President & Director Dr. Todd C. Brady M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.